RareResearch.AI
← Back to atlas

Y291*

NonsenseN1PathogenicCytoplasmic · predicted
Nonsense variant · truncation point at position 291 · N-terminal cytoplasmic (intrinsically disordered) · WFS1 (Wolframin)

N1NMD-targeted — null allele

Wild-type vs Translated Product

Wild-type · full length
Full wild-type wolframin · 890 aa — truncation point at residue 291
Fullscreen ↗
Translated product
Native sequence to residue 290; everything highlighted (residues 291–890) is lost
Fullscreen ↗

Left: full-length wild-type wolframin (890 aa) with the truncation point at residue 291 marked. Right: the same model with the lost region (residues 291–890) marked — what the nonsense transcript fails to produce as native protein.

Structural / NMD Prediction

Variant type
Nonsense
NMD status
NMD-targeted
high confidence
Schema
N1
NMD-targeted — null allele
Native protein retained
32.6%

Stop codon at position 291 is more than 50 nt upstream of the last exon-exon junction (~aa 413). The 50-nt rule predicts the transcript is degraded by nonsense-mediated decay. No truncated protein is produced; functionally a null allele.

Therapeutic Implication · N1

Transcript degraded by NMD; no truncated protein produced. Therapeutic options: (a) translational readthrough drugs — Ataluren/PTC124, gentamicin-class aminoglycosides — may rescue partial readthrough; (b) gene therapy — allele replacement is the higher-yield long-term path. Pharmacological chaperones do not apply since no protein is made.

Protein Domains

Retained (aa 1–290)
Lost / non-native (downstream)
  • Transmembrane helix 1311331
  • Cytoplasmic loop 1332340
  • Transmembrane helix 2341361
  • Lumenal loop 1362370
  • Transmembrane helix 3371391
  • Cytoplasmic loop 2392400
  • Transmembrane helix 4401421
  • Lumenal loop 2422431
  • Transmembrane helix 5432452
  • Cytoplasmic loop 3453461
  • Transmembrane helix 6462482
  • Lumenal loop 3483496
  • Transmembrane helix 7497517
  • Cytoplasmic loop 4518532
  • Transmembrane helix 8533553
  • Lumenal loop 4554573
  • Transmembrane helix 9574594
  • Cytoplasmic loop 5 / pre-lumenal595599
  • C-terminal ER-lumenal (calcium binding, calmodulin, chaperone)600890

Clinical Evidence

ClinVar classificationPathogenic
Review statuscriteria provided, multiple submitters, no conflicts
Associated conditionsWolfram syndrome
Population frequency (gnomAD v4)Ultra-rare · AF 0.000068%
cDNA changec.873C>G
ClinVar variantNM_006005.3(WFS1):c.873C>G (p.Tyr291Ter)
ClinVar accessionVCV000212616
Last evaluated2025/02/17 00:00

Observed at very low frequency in gnomAD.

Classified for2★ documented assertion

ClinVar classifies this variant as Pathogenic for Wolfram syndrome (classic) (autosomal recessive, OMIM 222300). Classic Wolfram syndrome is recessive: a single copy does not produce it, and this classification says nothing about a carrier's own risk.

  • Wolfram syndrome (classic)autosomal recessive · OMIM 222300submitted as: Wolfram syndrome
  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 2★ multiple submitters, no conflicts. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
AF 0.000068% · 1 / 1,461,786 alleles
Homozygotes
0

Every ancestry group with observed alleles falls below the reporting threshold (min 2 alleles, min 500 sampled) — too sparse to name a highest-frequency population.

No homozygotes reported in gnomAD v4. For a recessive allele this is expected and is not, on its own, evidence either way.

Ancestry groupAllele freq.AC / ANHom.Carrier est.
European (non-Finnish) · under-sampled0.000090%1 / 1,111,9500

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the Y291* card below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals matched to this N1 nonsense variant and its domain context.

Full Variant Card

Y291* — WFS1 Molecular Atlas Card

Variant type: Nonsense (premature stop codon) Position: 291 Wild-type residue: Tyrosine (Y) Domain context (where the stop falls): N-terminal cytoplasmic (intrinsically disordered)


Schema category: N1 — NMD-targeted — null allele

Transcript degraded by NMD; no truncated protein produced. Therapeutic options: (a) translational readthrough drugs — Ataluren/PTC124, gentamicin-class aminoglycosides — may rescue partial readthrough; (b) gene therapy — allele replacement is the higher-yield long-term path. Pharmacological chaperones do not apply since no protein is made.


NMD prediction

  • Status: NMD-targeted
  • Confidence: high
  • Reasoning: Stop codon at position 291 is more than 50 nt upstream of the last exon-exon junction (~aa 413). The 50-nt rule predicts the transcript is degraded by nonsense-mediated decay. No truncated protein is produced; functionally a null allele.

Truncation analysis

  • Residues retained: 1 – 290 (32.6% of full-length protein)
  • Residues lost: 291 – 890 (67.4% of full-length protein)

Retained domains

(no domains fully retained)

Partially retained at truncation point

  • N-terminal cytoplasmic (intrinsically disordered) — partial: aa 1–290 retained, aa 291–310 lost

Lost domains

  • Transmembrane helix 1 (aa 311–331)
  • Cytoplasmic loop 1 (aa 332–340)
  • Transmembrane helix 2 (aa 341–361)
  • Lumenal loop 1 (aa 362–370)
  • Transmembrane helix 3 (aa 371–391)
  • Cytoplasmic loop 2 (aa 392–400)
  • Transmembrane helix 4 (aa 401–421)
  • Lumenal loop 2 (aa 422–431)
  • Transmembrane helix 5 (aa 432–452)
  • Cytoplasmic loop 3 (aa 453–461)
  • Transmembrane helix 6 (aa 462–482)
  • Lumenal loop 3 (aa 483–496)
  • Transmembrane helix 7 (aa 497–517)
  • Cytoplasmic loop 4 (aa 518–532)
  • Transmembrane helix 8 (aa 533–553)
  • Lumenal loop 4 (aa 554–573)
  • Transmembrane helix 9 (aa 574–594)
  • Cytoplasmic loop 5 / pre-lumenal (aa 595–599)
  • C-terminal ER-lumenal (calcium binding, calmodulin, chaperone) (aa 600–890)

Clinical evidence

Inheritance and scope

Pathogenic — for Wolfram syndrome (classic) (autosomal recessive, OMIM 222300)

ClinVar classifies this variant as Pathogenic for Wolfram syndrome (classic) (autosomal recessive, OMIM 222300). Classic Wolfram syndrome is recessive: a single copy does not produce it, and this classification says nothing about a carrier's own risk.

Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient. Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

  • Classification: Pathogenic
  • Review status: criteria provided, multiple submitters, no conflicts
  • Associated conditions: Wolfram syndrome
  • cDNA change: c.873C>G
  • ClinVar accession: VCV000212616
  • Last evaluated: 2025/02/17 00:00
  • Submissions: 1

Population frequency

  • Frequency: Ultra-rare · AF 0.0001%
  • Allele count: 1 of 1,461,786 alleles (~730,893 individuals)
  • gnomAD variant ID: 4-6300668-C-G
  • Interpretation: Observed at very low frequency in gnomAD.

Source: gnomAD v4 joint exome + genome callset, cached locally. Frequency is population evidence only — it does not by itself establish or exclude pathogenicity.


Why this variant matters

This variant is biologically silent — the transcript is degraded before any truncated protein can be made. From a therapeutic standpoint, that simplifies the problem (one null allele) and points toward two specific paths: readthrough compounds that exploit the ribosome's natural ability to bypass premature stops, or gene-level replacement therapy. The atlas surfaces this clarity directly.


Card generated by wolfram-atlas-batch skill (v1) on 2026-07-31T21:01:26.978596Z. NMD rule and schema definitions: reference/nmd_rules.md, reference/card_schema_extension.md. WFS1 reference: UniProt O76024, AlphaFold model v6.